The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

1 Jun 2015 07:00

RNS Number : 7164O
Fastnet Oil & Gas PLC
01 June 2015
 

1 June 2015

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Corporate Update

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focused on near-term exploration and appraisal acreage in Morocco and the Celtic Sea, provides the following corporate update.

 

Highlights:

Significant reduction in G&A, with overhead down over 40% since the end of 2014, with further reductions expected.Cash on the balance sheet of USD$16.2 million at 31 May 2015.The Company continues to evaluate M&A opportunities capable of delivering significant shareholder value.Discussions have commenced with the Department of Communications, Energy and Natural Resources following the expiration of licensing options on 31 May 2015 of 12/2 ("Molly Malone") and 12/3 ("Mizzen").Applications have been submitted for new licensing options over high-graded portions of the previous Mizzen and Molly license areas.

 

Corporate

Fastnet provides the following update on the Molly Malone and Mizzen licensing options in the Celtic Sea (together the "Options"). In the absence of Fastnet having committed to certain additional obligations including drilling, the Options expired on 31 May 2015.

Fastnet has today submitted applications for new licensing options over portions of the original licensing option areas. The new licensing option areas were high-graded based on the technical evaluation carried out since the original licensing options were first awarded. The Minister of State at the Department of Communications, Energy and Natural Resources will consider applications received in respect of these areas in the coming months and the Company will provide an update on this process when more information is available. 

Fastnet remains excited by the quality of its Celtic Sea portfolio and will continue to technically evaluate and high-grade its acreage in the Celtic Sea. Numerous prospects and leads have been extensively mapped over the last 6 months based on newly acquired and reprocessed seismic data throughout the currently held option areas. The Company is in the process of compiling new resource estimates for the portfolio of prospects and leads.

The Company also continues to evaluate M&A opportunities in the current market environment which will deliver significant shareholder value while focussing on developing its Celtic Sea portfolio.

 

Financial

The Company has undergone a comprehensive review of general and administration costs and has reduced overheads by over 40% since December 2014 to $1.9m a year. Further corporate and overhead costs reductions are ongoing.

The Company's cash balance at 31 May 2015 was $16.2 million.

 

Carol Law, CEO of Fastnet, commented:

"We have been conducting detailed due diligence on a number of merger and acquisition opportunities in the sector, but as of yet have not identified one which would be accretive to shareholders and therefore be a suitable use of our available cash. We have taken steps to preserve our cash through reducing ongoing costs and have nearly halved our G&A expenses since the end of 2014. In the immediate future we will continue to scrutinize costs to further reduce overhead and evaluate targeted merger and acquisition opportunities aimed at enhancing value for our shareholders."

 

For further information please contact:

Fastnet Oil & Gas plc

+353 (1) 644 0007

Carol Law, Chief Executive Officer

 

Cathal Friel, Non-Executive Chairman

 

 

 

Shore Capital

+44 (0) 20 7408 4090

Nomad

 

Bidhi Bhoma, Edward Mansfield

 

 

 

Corporate Broking

 

Jerry Keen

 

 

 

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

 

John Frain, Anthony Farrell

 

 

 

Camarco

+44 (0) 20 3757 4980

Billy Clegg, Georgia Mann

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEIFMUFISESI
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.